NGGT

Focus: NGGT is a newly public (2024) gene therapy biotech focused on rare diseases and ophthalmology, operating at pre-revenue scale with 51-200 employees from Walnut Creek, CA.

Rare Diseases Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

About NGGT

AI assessmentNot Hiring

No open roles listed right now. Follow NGGT to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NGGT002

Phenylketonurias

PHASE_1_2

Clinical Trials (1)

NCT06332807AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

Phase 1/2

Help build intelligence for NGGT

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public gene therapy company with focused pipeline in high-value rare disease and ophthalmology markets
Early-stage role offers potential for significant equity upside and outsized individual impact in a lean 51-200 person organization
Gene therapy modality addresses significant unmet needs in rare diseases like phenylketonuria and Bietti dystrophy with limited competitive alternatives

Watch Out For

Pre-revenue stage with no active hiring (0 open roles) suggests company may be in stealth/integration mode post-IPO with unclear near-term hiring trajectory
Only Phase 1/2 programs with no Phase 3 data and minimal clinical validation creates execution risk and extended timeline to value inflection
Newly founded (2024) and public with sparse disclosed financials (no revenue, R&D, or cash position data) limits visibility into burn rate and runway

Generated by Claude from NGGT's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NGGT002

Phenylketonurias

PHASE_1_2

Clinical Trials (1)

NCT06687733Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects

Phase 1/2

NGGT001

Bietti Crystalline Corneoretinal Dystrophy

PHASE_1_2

Clinical Trials (1)

NCT06706427Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects

Phase 1/2